Compare FEIM & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | ZVRA |
|---|---|---|
| Founded | 1961 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 664.7M |
| IPO Year | 1994 | 2015 |
| Metric | FEIM | ZVRA |
|---|---|---|
| Price | $67.04 | $11.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $95.50 | $25.25 |
| AVG Volume (30 Days) | 203.9K | ★ 861.8K |
| Earning Date | 12-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | 0.41 | ★ 1.03 |
| Revenue | $63,227,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $30.80 | $43.42 |
| Revenue Next Year | $26.18 | $16.20 |
| P/E Ratio | $166.38 | ★ $11.52 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $26.05 | $8.01 |
| 52 Week High | $89.76 | $15.04 |
| Indicator | FEIM | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 53.59 |
| Support Level | $54.70 | $9.58 |
| Resistance Level | $73.81 | $12.19 |
| Average True Range (ATR) | 4.54 | 0.56 |
| MACD | 0.57 | 0.19 |
| Stochastic Oscillator | 67.68 | 66.06 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.